Author of

• 18502

  +

  P3.02c - Poster Session with Presenters Present (ID 472)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18602

    +

    P3.02c-100 - Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC) (ID 4935)

    14:30 - 14:30  |  Author(s): C. Aguayo
    • Abstract

    Background:
    Patients with metastatic NSCLC progressing to 1L have a poor prognosis. Nivolumab is an anti-PD-1 monoclonal antibody, which has shown to prolong overall survival (OS) in patients who have progressed to platinum-based chemotherapy. We report our experience with nivolumab in pretreated metastatic NSCLC patients.
    
    Methods:
    Retrospective study of patients with metastatic NSCLC treated with nivolumab (3 mg/kg every 2 weeks) in second line (2L) and subsequent lines (SL). We evaluate response rate (RR), progression-free survival (PFS), OS and toxicity.
    
    Results:
    Twenty patients were included (2L: 17, SL: 13). Median age: 68 years. Histology: Adenocarcinoma (60%), Squamous cell (33%), Large cell (7%). ECOG PS: ECOG 0-1 (83%), ECOG 2 (17%). Median number of cycles: 8. RR (Twenty-three patients evaluable for response): Complete response (9%), partial response (35%), stable disease (26%), disease progression (30%). Objetive response rate (ORR) in 2L vs SL: 55% vs 33%, p=0.30. ORR in squamous vs non-squamous: 25% vs 47%, p=0.40. Median follow-up: 6 months. PFS and OS events at the time of analysis: 43% and 33%, respectively. Median PFS and OS: 7 months and not reached (NR), respectively. PFS in 2L vs SL: NR vs 5 months, HR 0.81, p=0.71. PFS in squamous vs non-squamous: 5 months vs NR, HR 1.39, p=0.58. OS in 2L vs SL: NR vs NR, HR 1.53, p=0.50. OS in squamous vs non-squamous: 7 months vs NR, HR 2.61, p=0.14. The incidence of adverse events was low. The most frequent toxicity (any grade) was asthenia (67%). A patient with chronic liver disease had hepatotoxicity grade 1 and continued treatment. Three patients discontinued treatment due to toxicity: pneumonitis grade 3 (1), rash grade 3 (1), impaired renal function grade 3 (1). There were no toxic deaths.
    
    Conclusion:
    In clinical practice, nivolumab is effective and safe in 2L and SL in patients with metastatic NSCLC.